Pharmaceutical industry – Page 4
-
FeatureWho will pay for new antibiotics?
Governments around the world are starting to consider alternative funding models and incentives for antibiotics. Katrina Megget asks if it is enough
-
OpinionSurviving in the war of all against all
Cancers and bacteria develop resistance to drugs in remarkably similar ways
-
FeatureCharting the rise in antimicrobial resistance
We look at the data behind antibiotic drug discovery and development, bacterial resistance and the financial problems with the current business model
-
ArticleCPHI Barcelona 2023: forging collaborations for a promising future in the pharmaceutical sector
CPHI creates connections and inspires partnerships across the global pharma community
-
OpinionCould cheap CRO rates threaten to destabilise biotech?
Pharmaceutical pipelines are heavily dependent on contract research organisations; we can’t afford for them to fail
-
OpinionBeyond the ChatGPT hype
Large language models can be powerful tools for chemistry if we acknowledge their limits
-
BusinessFines upheld for Advanz Pharma over thyroid drug price increases
UK competition tribunal rules liothyronine pricing ’excessive’ and ‘deliberate’
-
OpinionNavigating the literature torrent
It’s humanly impossible to filter and read everything worthwhile – let’s embrace assistance
-
BusinessAntibodies face Alzheimer’s reality
Companies are convincing regulators, but will doctors use them, and will providers pay for them?
-
BusinessBiogen to cut 1000 more jobs by 2025
Biotech giant has also agreed to buy Reata Pharmaceuticals for $7.3 billion
-
BusinessIllumina’s Grail quest results in epic fine
EU and US competition authorities object to firms completing merger without approval
-
ArticleMimicking our eyes’ sun protection
Sóliome is developing sunscreens based on natural UV-filtering peptides
-
BusinessJ&J subsidiary sues more talc researchers
Lawsuit claims another study linking talc use to cancer is fraudulent
-
BusinessRevolutionising RSV prevention
New vaccines and a long-acting antibody aim to protect older adults and babies from respiratory syncytial virus
-
ResearchAI can suggest Covid-19 antivirals from protein sequence alone
IBM model can also find molecules that bind at different sites on target proteins
-
OpinionBringing drug manufacturing back home
Pharmaceutical supply chains are international, complex and opaque. Is there a better way?
-
ResearchColour-changing liquids could flag cold chain breaches for medicines
Device offers simple and reliable monitoring with no electronic waste
-
BusinessUS trade regulator sues to block Amgen–Horizon merger
Federal Trade Commission has concerns that union will allow Amgen to stifle potential competition for Horizon’s drugs
-
BusinessThe diabetes drugs aiming to aid weight loss
Can peptide hormone mimics avoid the side effect pitfalls of previous weight loss treatments?
-
BusinessUS supreme court confirms Amgen’s cholesterol antibody patents invalid
Decision could mean patent descriptions need to be even more detailed, and hence expensive